Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy最新文献

{"title":"Association of Serum Phosphorus Levels With QT Prolongation in Patients With End-Stage Kidney Disease: Insights From the Analysis of Peritoneal Dialysis Patients.","authors":"Sho Sasaki, Kiichiro Fujisaki, Hikaru Uematsu, Masato Nishimura, Toshiaki Nakano, Masanori Abe, Norio Hanafusa, Nobuhiko Joki","doi":"10.1002/1744-9987.70184","DOIUrl":"https://doi.org/10.1002/1744-9987.70184","url":null,"abstract":"<p><strong>Background: </strong>Serum phosphorus (P) levels have been associated with QT interval prolongation in patients undergoing hemodialysis. However, it is unclear whether this association exists in patients undergoing peritoneal dialysis (PD) in the absence of acute electrolyte fluctuations.</p><p><strong>Methods: </strong>This cross-sectional study was conducted among adult patients on maintenance PD who were enrolled in the Japanese Society for Dialysis Therapy and Renal Data Registry in 2020. After assessing patient characteristics, a linear regression analysis was performed with serum calcium (Ca) and P levels as exposures and rate-corrected QT (QTc) interval as the outcome.</p><p><strong>Results: </strong>This study included 3566 patients with a mean QTc of 449.1 ± 34.5. Of these, 251 (7.0%) had QT interval prolongation (QTc > 500 msec). Univariate analysis showed a statistically significant association between lower corrected Ca and longer QTc interval, as well as higher P and longer QTc. Only the association between higher P and longer QTc remained statistically significant in multivariate analysis. Restricted cubic spline showed that QTc tended to increase with lower corrected Ca, whereas QTc time tended to increase with higher phosphate levels.</p><p><strong>Conclusion: </strong>An association between hypocalcemia and QT interval prolongation was confirmed in patients undergoing PD, similar to findings in hemodialysis. However, unlike in hemodialysis, an association between serum P levels and QT interval was found only in cases of hyperphosphatemia and not in the context of hypophosphatemia and QT interval prolongation.</p>","PeriodicalId":94253,"journal":{"name":"Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2026-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148407716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Forecasting the Dialysis Burden in Japan: Validation-Based Projections of Prevalence and Incidence Through 2050.","authors":"Hatice Şahin, Berrak Itır Aylı, Nüket Paksoy","doi":"10.1002/1744-9987.70183","DOIUrl":"https://doi.org/10.1002/1744-9987.70183","url":null,"abstract":"<p><strong>Background: </strong>Japan has one of the highest dialysis prevalence rates worldwide and a shrinking, aging population. Whether dialysis burden has entered a sustained post-peak phase or whether recent declines partly reflect pandemic-related disruptions remains uncertain.</p><p><strong>Methods: </strong>We analyzed nationwide data from the Japanese Society for Dialysis Therapy Renal Data Registry (1983-2022) to project dialysis prevalence and incidence through 2050. Seven forecasting approaches were implemented, including classical time-series models, demographic regression models, machine-learning algorithms, and a performance-weighted ensemble. Models were trained on 1983-2017 data and validated against a holdout period (2018-2022) encompassing the historical peak in dialysis prevalence in order to forecast accuracy using RMSE, MAE, and MAPE.</p><p><strong>Results: </strong>Dialysis prevalence increased from 52 505 patients in 1983 to a peak of 349 700 in 2021, followed by a decline in 2022, though the contribution of COVID-19-related excess mortality to this inflection cannot be excluded. During validation, the ensemble model demonstrated the highest predictive accuracy for prevalence and incidence (MAPE 0.60% and 0.48% respectively). Individual models produced divergent long-term trajectories, ranging from substantial decline to continued growth. The ensemble model projected a gradual decrease in dialysis prevalence to approximately 322 000 patients by 2050 (-7.2% vs. 2022) and a 24.4% reduction in annual dialysis incidence.</p><p><strong>Conclusions: </strong>Dialysis prevalence in Japan shows signs of a potential shift toward a downward trend with future burden increasingly driven by demographic change rather than rising incidence. Ensemble forecasting grounded in empirical validation provides balanced projections and highlights substantial uncertainty across modeling paradigms. Japan's experience offers important insights for other aging societies planning future kidney care services.</p>","PeriodicalId":94253,"journal":{"name":"Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2026-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148400322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety of Daprodustat for the Treatment of Chronic Kidney Disease Anemia: Final Analysis of a Multicenter Postmarketing Surveillance Study in Japan.","authors":"Tadao Akizawa, Kyomi Kanaya, Kiyomi Aizawa, Masanori Onoki, Hirofumi Ozeki, Kazuko Suzuki, Ai Hayashi, Tomohiko Asamura","doi":"10.1002/1744-9987.70182","DOIUrl":"10.1002/1744-9987.70182","url":null,"abstract":"<p><strong>Introduction: </strong>This final analysis of a multicenter, prospective postmarketing surveillance study evaluated the safety of daprodustat in patients with chronic kidney disease anemia in routine clinical practice in Japan.</p><p><strong>Methods: </strong>Patients who initiated daprodustat between September 2020 and July 2022 were registered. The observation period was 52 weeks from treatment start or until discontinuation to assess overall safety, with an additional 52-week follow-up for cancer-related events.</p><p><strong>Results: </strong>Of 1634 patients in the safety analysis set, adverse drug reactions (ADRs) occurred in 5.6% (4.8% not undergoing dialysis; 6.9% undergoing peritoneal dialysis; 6.6% undergoing hemodialysis) and serious ADRs in 2.2%. ADRs related to thromboembolism, hypertension, cardiovascular events, cancer, and retinal hemorrhage were reported in less than 1%, with no progression of autosomal dominant polycystic kidney disease. During follow-up, no increase in cancer-related events was observed.</p><p><strong>Conclusions: </strong>No new safety concerns were identified for daprodustat in the real-world setting in Japan.</p><p><strong>Trial registration: </strong>GSK study: 214119.</p>","PeriodicalId":94253,"journal":{"name":"Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2026-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148400469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survival Analysis and Risk Factors of Mortality of Hemodialysis Patients With Diabetic Nephropathy: Data From the Indonesian Renal Registry.","authors":"Yoga Mulia Pratama, Ratih Tri Kusuma Dewi, Agung Susanto, Satriyo Budhi Susilo, Eti Poncorini Pamungkasari, Bambang Purwanto, Afiatin, Dwi Lestari Partiningrum, Ayudyah Nurani, Aryo Suseno, Santy Ayu Puspita Perdhana","doi":"10.1002/1744-9987.70181","DOIUrl":"https://doi.org/10.1002/1744-9987.70181","url":null,"abstract":"<p><strong>Background: </strong>Diabetic nephropathy occurs in more than 20% of people with diabetes. Diabetic nephropathy has a high mortality rate and is one of the most common causes of end-stage renal disease in hemodialysis (HD) units. Analysis of survival rates and risk factors of mortality of HD patients with diabetic nephropathy is needed to determine patient prognosis, modify risk factors, and provide evaluation for HD quality, especially in a limited resource setting.</p><p><strong>Methods: </strong>This study is a retrospective cohort study using data from the Indonesian Renal Registry (IRR) in Central Java during 2018-2022, followed by 1 year of monitoring until the patient died or dropped out of HD. The variables assessed in this study were age, sex, hypertension status, HD vascular access, and hemoglobin.</p><p><strong>Results: </strong>There were 1184 patients who met the study criteria. All of the patients had a twice-weekly HD setting. The survival rate of HD patients with diabetic nephropathy was 90.7% for the first 90 days and 86.7% for 1-year survival. Hypertension status and initial vascular access affected the survival rate of HD patients with diabetic nephropathy. Based on the Cox proportional hazard regression model, the risk factors of mortality in HD patients with diabetic nephropathy were hypertension (HR = 1.530, 95% CI: 1.104-2.119) and femoral vein puncture (HR = 2.663, 95% CI: 1.777-3.990).</p><p><strong>Conclusion: </strong>The 1-year survival rate of HD patients with diabetic nephropathy in Central Java, Indonesia, is 86.7%. Risk factors of mortality in HD patients with diabetic nephropathy are hypertension and the use of femoral vein puncture as initial vascular access.</p>","PeriodicalId":94253,"journal":{"name":"Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2026-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148378880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Impact of Monocyte-to-HDL Ratio and Triglyceride-Glucose Index on Arterial Stiffness in Hemodialysis Patients.","authors":"Ibrahim Halil Bilen, Nazife Nur Ozer Sensoy, Orcun Altunören, Özkan Güngör","doi":"10.1002/1744-9987.70180","DOIUrl":"https://doi.org/10.1002/1744-9987.70180","url":null,"abstract":"<p><strong>Background: </strong>Arterial stiffness is an important cardiovascular risk marker in hemodialysis patients. The monocyte-to-high-density lipoprotein cholesterol ratio (MHR) and triglyceride-glucose (TyG) index are laboratory-based markers related to inflammation, lipid metabolism, and insulin resistance. This study evaluated their association with arterial stiffness.</p><p><strong>Methods: </strong>This cross-sectional study included 120 adults receiving maintenance hemodialysis. Arterial stiffness was assessed by pulse wave velocity (PWV), and patients were classified as PWV > 10 or ≤ 10 m/s. Correlation and multivariable linear regression analyses were performed to identify factors associated with PWV.</p><p><strong>Results: </strong>A total of 29 patients had PWV > 10 m/s. PWV was associated with both the TyG index and MHR in unadjusted analyses. Patients with arterial stiffness were older and had higher systolic blood pressure. In multivariable analysis, only age and systolic blood pressure remained independently associated with PWV.</p><p><strong>Conclusions: </strong>Age and systolic blood pressure were the main determinants of arterial stiffness. Although MHR and the TyG index correlated with PWV, their independent predictive value appeared limited.</p>","PeriodicalId":94253,"journal":{"name":"Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148364700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Evaluation of Hemodiafiltration, Hemoperfusion, and Standard Hemodialysis on Efficacy, Inflammatory Control, Dialysis Adequacy, and Safety in End-Stage Renal Disease: A Prospective Observational Study.","authors":"Hongwei Zuo, Weisi Dai, Jie Mao, Mei Ye, Xingshan Lu, Xiaocui Zhang","doi":"10.1002/1744-9987.70178","DOIUrl":"https://doi.org/10.1002/1744-9987.70178","url":null,"abstract":"<p><strong>Background: </strong>Chronic micro-inflammation in patients with end-stage renal disease (ESRD) is a significant driver of cardiovascular complications and diminished quality of life. While standard hemodialysis (SHD) effectively manages small-molecule clearance, its ability to remove medium-to-large uremic toxins-the primary catalysts of systemic inflammation-remains limited. This study aimed to evaluate the comparative clinical benefits of hemodiafiltration (HDF) and hemoperfusion (HDP) relative to SHD, specifically focusing on inflammatory control, dialysis adequacy, and patient safety.</p><p><strong>Methods: </strong>This was a 10-week, single-center, non-randomized prospective observational study evaluating 365 end-stage renal disease (ESRD) patients divided into three cohorts: standard hemodialysis (SHD, n = 145, thrice-weekly), online hemodiafiltration (HDF, n = 115, twice-weekly hemodialysis plus once-weekly HDF), and hemoperfusion (HDP, n = 105, twice-weekly hemodialysis plus once-monthly hemoperfusion). Primary endpoints were restricted to short-term surrogate outcomes, including shifts in serum inflammatory markers (interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), C-reactive protein (CRP)) and clearance adequacy indices (Kt/V, URR).</p><p><strong>Results: </strong>Baseline characteristics were well-balanced across all three cohorts. Following 10 weeks of treatment, the HDF (84.2%) and HDP (77.1%) groups demonstrated significantly higher effective treatment rates (defined by clinical symptom improvement and biochemical stability, a composite of symptomatic improvement and biochemical stability) compared to the SHD group (61.4%; p < 0.05). Advanced modalities achieved increased association with biomarker reduction of middle-molecule toxins, with HDF showing the most profound reductions in IL-6, TNF-α, and CRP (p < 0.001). Dialysis adequacy was significantly improved in the HDF group, which showed the highest increases in dialysis adequacy. While the incidence of acute complications such as hypotension and muscle cramps did not differ significantly between groups, both HDF and HDP cohorts reported a notable reduction in post-dialysis fatigue compared to SHD (14% and 16% vs. 19%, respectively). However, HDF and HDP cohorts experienced lower incidences of cognitive dysfunction.</p><p><strong>Conclusions: </strong>Over a 10-week observation framework, advanced hybrid modalities (HDF and HDP) are independently associated with superior clearance of middle-to-large molecular uremic toxins and attenuated systemic inflammation compared to SHD. However, these short-term surrogate improvements did not translate into a statistically significant reduction in clinical adverse events or post-dialysis fatigue, indicating the need for long-term longitudinal evaluation.</p>","PeriodicalId":94253,"journal":{"name":"Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2026-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148364703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Establishing an Apheresis Medicine Program in a Resource-Constrained Setting: A 5-Year Experience From Lagos, Nigeria.","authors":"Folasade Adelekan-Popoola, Shakirat Gold-Olufadi, Olufunto Olufela Kalejaiye, Abdullateef Ogala, Rasheed A Balogun","doi":"10.1002/1744-9987.70176","DOIUrl":"https://doi.org/10.1002/1744-9987.70176","url":null,"abstract":"<p><strong>Background: </strong>Establishing a comprehensive apheresis medicine program in a resource-constrained setting presents significant structural, financial, and logistical challenges. Despite the growing clinical importance of apheresis services globally, published experience from sub-Saharan Africa remains sparse. This study describes the 5-year operational experience of building and sustaining an Apheresis Medicine program at Next Hematology Medicare, a private hematology center in Lagos, Nigeria, including the challenges encountered, solutions implemented, and clinical outcomes achieved.</p><p><strong>Methods: </strong>A retrospective review of all apheresis procedures performed between May 2020 and December 2025 was conducted. Therapeutic apheresis procedures included automated red cell exchange transfusion (RCE), therapeutic plasma exchange (TPE) and leukocytapheresis. Donor apheresis procedures comprised single-donor apheresis platelet collections for transfusion and stem cell collection (SCC) by donors. Data on patient demographics, clinical indications, procedural outcomes, and geographic distribution of platelet delivery were collected and analyzed.</p><p><strong>Results: </strong>A total of 2405 apheresis procedures were performed over the 5-year period. Donor apheresis platelet (AP) collection was the most frequently performed procedure (n = 1772; 73.7%), followed by RCE (n = 617; 25.7%) as the most common therapeutic apheresis modality. TPE accounted for 12 procedures (n = 12; 0.5%), while leukocytapheresis (n = 2; < 0.1%) and SCC (n = 1; < 0.1%) were performed infrequently. For AP, Sepsis/DIC was the leading transfusion indication (n = 968; 54.6%). RCE was performed predominantly for patients with sickle cell anemia (SCA), with intractable recurrent vaso-occlusive crises (VOC) being the most common indication (n = 382; 61.9%). RCE significantly reduced hemoglobin S (HbS%) from 93.13% ± 12.4% to 18.74% ± 4.2% (p < 0.001) and improved hematocrit from 16.34% ± 3.5% to 26.01% ± 4.2% (p < 0.001). TPE was primarily indicated for neurological and transplant-related conditions. Apheresis platelets were distributed nationally across all six geopolitical zones and internationally.</p><p><strong>Conclusion: </strong>A fully functional Apheresis Medicine program can be successfully established and sustained in a resource-constrained low- and middle-income country (LMIC) setting, delivering outcomes comparable to high-income country benchmarks. RCE showed significant hematological benefits for patients with SCA, and donor apheresis platelet delivery extended care across all Nigerian geopolitical zones. The operational framework described here, addressing funding, infrastructure, staffing, licensing, and blood safety, provides a possibly replicable model for Apheresis Medicine program development across sub-Saharan Africa.</p>","PeriodicalId":94253,"journal":{"name":"Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2026-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148348046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum Myonectin Levels Are Positively Associated With Physical Function and Lower Frailty-Related Limitation in Maintenance Hemodialysis Patients: A Cross-Sectional Study.","authors":"Kenichi Kono, Yoshifumi Moriyama, Koji Ohashi, Naoya Otaka, Minako Tatsumi, Toyoaki Murohara, Noriyuki Ouchi, Satoru Oshima","doi":"10.1002/1744-9987.70177","DOIUrl":"https://doi.org/10.1002/1744-9987.70177","url":null,"abstract":"<p><strong>Background: </strong>Maintenance hemodialysis (MHD) patients frequently suffer from frailty, characterized by reduced physical function and poor prognosis. Myokines, such as myonectin, secreted by muscle, are emerging regulators of systemic health. This study investigated the relationship between serum myonectin, adipokines (adiponectin, omentin), and objective measures of physical function in MHD patients, excluding previously planned cardiac data.</p><p><strong>Methods: </strong>This cross-sectional study included 23 MHD outpatients. We assessed physical function using the Short Physical Performance Battery (SPPB) score and the 5-Sit-to-Stand Test (5-SST). We also measured body composition, physical activity (accelerometer-derived step count), and serum concentrations of myonectin, adiponectin, and omentin. Correlation analysis and comparison between high (≧ median) and low (< median) myonectin groups were performed.</p><p><strong>Results: </strong>Serum myonectin was positively correlated with Body Mass Index (BMI) and the SPPB score. No significant correlations were observed between myonectin and other physical function or physical activity indicators. Furthermore, the high myonectin group showed significantly better performance compared to the low group, completing the 5-SST in a shorter time and achieving a higher SPPB score. Adiponectin showed significant inverse correlations with BMI, muscle mass, and fat mass.</p><p><strong>Conclusion: </strong>Serum myonectin levels are positively associated with superior physical function (SPPB) and faster lower-extremity performance (5-SST) in MHD patients. Myonectin may serve as a simple, novel biomarker to identify MHD patients with better preserved functional capacity and potentially less frailty-related limitation. These findings underscore the critical role of muscle health in maintaining function in this vulnerable population.</p>","PeriodicalId":94253,"journal":{"name":"Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2026-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148348022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Arterial Stiffness and Geriatric Syndromes in Older Adults With Chronic Kidney Disease: A Cross-Sectional Study.","authors":"Serife Tol Ozen, Neziha Erken, Ilyas Ozturk, Feyza Nur Sarısık, Esra Tasgetiren, Orcun Altunoren, Ozkan Gungor, Ertugrul Erken","doi":"10.1002/1744-9987.70173","DOIUrl":"https://doi.org/10.1002/1744-9987.70173","url":null,"abstract":"<p><strong>Introduction: </strong>Arterial stiffness, a hallmark of vascular aging. It may link chronic kidney disease (CKD) to frailty and functional decline. This study aimed to evaluate the associations between arterial stiffness and geriatric syndromes.</p><p><strong>Methods: </strong>Individuals aged ≥ 60 years; 90 patients with stage 3b-5 CKD or receiving dialysis, and 90 age-matched healthy controls were included. Arterial stiffness was assessed using Pulse Wave Velocity (aPWV). Geriatric assessments for frailty, malnutrition, depression, polypharmacy, and dependence in daily living were evaluated. Multivariable regression was used to identify possible predictors for arterial stiffness.</p><p><strong>Results: </strong>aPWV was higher in the CKD group than in controls. Frailty, malnutrition, and depression were not associated with arterial stiffness in CKD patients. Arterial stiffness was significantly associated with increased dependency. However, age and systolic blood pressure seem to be major determinants for aPWV.</p><p><strong>Conclusion: </strong>aPWV is elevated in older adults with CKD, and it may reflect functional dependence.</p>","PeriodicalId":94253,"journal":{"name":"Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2026-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148240918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Experience With Performing Rheocarna Therapy via the Single-Needle Method for Treatment of Chronic Limb-Threatening Ischemia.","authors":"Yasutaka Yamauchi, Rie Tanaka, Reona Kawahira, Shingo Nabeta, Kouhei Naoi, Kazuhito Kitajima, Akira Wada, Tomonari Takagi, Norihiko Ohura, Akira Miyamoto","doi":"10.1002/1744-9987.70161","DOIUrl":"https://doi.org/10.1002/1744-9987.70161","url":null,"abstract":"<p><strong>Introduction: </strong>This study investigated the safety and efficacy of single-needle Rheocarna therapy for chronic limb-threatening ischemia (CLTI) with wounds.</p><p><strong>Methods: </strong>Six patients with CLTI involving ulcers unresponsive to revascularization underwent single-needle Rheocarna treatment. Changes in mean low-density lipoprotein cholesterol (LDL-C), fibrinogen, C-reactive protein (CRP), white blood cell (WBC) count, platelet count, blood flow, and wound improvement were compared between treatment initiation and completion.</p><p><strong>Results: </strong>The treatment never required discontinuation due to in-circuit coagulation or hypotension, and its safety was confirmed. After 10 treatment sessions, LDL-C and fibrinogen removal rates were 24.3% and 24.4%, respectively. Platelet, WBC, and CRP values did not change significantly over time. Blood flow increased during treatment and posttreatment. All patients experienced wound improvement and favorable clinical outcomes.</p><p><strong>Conclusion: </strong>Single-needle Rheocarna therapy is effective for wound healing in CLTI. If this method applies to nondialysis patients without arteriovenous fistulas, indications for Rheocarna therapy will likely expand.</p>","PeriodicalId":94253,"journal":{"name":"Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2026-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148207450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}